<DOC>
	<DOCNO>NCT00929071</DOCNO>
	<brief_summary>The study doctor give EVOLENCE® mixed Lidocaine people study see effectively reduces pain inject work correct nasolabial wrinkle . The product use study EVOLENCE® , currently market United States cosmetic correction soft tissue contour deficiency ( include wrinkle ) , approve U.S. Food Drug Administration ( FDA ) .</brief_summary>
	<brief_title>Safety Efficacy Addition 0.3 % Lidocaine With EVOLENCE®</brief_title>
	<detailed_description>The aim study determine admixture lidocaine effectively use mediate pain relief injection EVOLENCE® achieve cosmetic correction .</detailed_description>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Anesthetics , Local</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<criteria>Understanding voluntary signature ( include date ) inform consent document Healthy male female &gt; 18 year age Clinical evidence bilateral , fully visible age defect nasolabial area grade 2.0 , 2.5 , 3.0 Modified Fitzpatrick Wrinkle Scale ( MFWS section 6.5 ) Willingness receive EVOLENCE® injection area age defect ( wrinkle ) Willingness ability comply requirement protocol History multiple severe allergy ( food , drug , substance ) and/or anaphylactic shock Subjects history bleed disorder , receive chronic antiplatelet therapy chronic anticoagulant medication Subject lowdose aspirin therapy nonsteroidal antiinflammatory drug , interrupt least 10 day prior injection and/or resume within 1 week injection History allergy and/or sensitivity porcine , bovine human collagen , lidocaine , local anesthetic product natural rubber latex Autoimmune collagen vascular disease , connective tissue disease Active skin disease , inflammation relate condition infection , psoriasis herpes zoster near nasolabial fold area study entry and/or within 6 month prior study entry Previous tissue augmentation permanent implant hyaluronic acid within 6 month EVOLENCE® within 12 month treatment area Currently treat immunosuppressive drug , chemotherapy agent systemic steroid treat within last 3 month prior study entry Botulinumtoxin A within 6 week treatment area Received investigational product within 30 day prior study enrollment Females Childbearing Potential Any clinically significant organic disease medical condition opinion PI , make subject poor candidate participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>wrinkle</keyword>
	<keyword>dermal filler</keyword>
	<keyword>collagen</keyword>
	<keyword>soft tissue augmentation</keyword>
	<keyword>lidocaine</keyword>
	<keyword>aesthetic</keyword>
</DOC>